Zenas BioPharma, Inc. (ZBIO) – What Are Researchers Saying About This Stock?

Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) have earned an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $46.71.

ZBIO has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Zenas BioPharma in a research note on Tuesday, October 6th. HC Wainwright reiterated a “buy” rating and issued a $44.00 target price on shares of Zenas BioPharma in a report on Tuesday, October 13th. Citigroup raised their price target on shares of Zenas BioPharma from $41.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, September 30th. Guggenheim restated a “buy” rating and set a $55.00 price target on shares of Zenas BioPharma in a report on Wednesday, September 30th. Finally, Wedbush restated an “outperform” rating and set a $45.00 price target on shares of Zenas BioPharma in a report on Wednesday, September 30th.

Zenas BioPharma Stock Performance

Shares of Zenas BioPharma stock opened at $24.84 on Monday. The stock has a fifty day simple moving average of $30.16 and a 200 day simple moving average of $25.50. Zenas BioPharma has a 12-month low of $13.50 and a 12-month high of $44.60. The company has a market capitalization of $1.62 billion, a P/E ratio of -2.76 and a beta of -0.90. The company has a current ratio of 9.93, a quick ratio of 9.93 and a debt-to-equity ratio of 1.57.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The company had revenue of $1.00 million during the quarter, compared to analyst estimates of $15.00 million. On average, sell-side analysts anticipate that Zenas BioPharma will post -5.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zenas BioPharma

A number of hedge funds and other institutional investors have recently modified their holdings of ZBIO. BlackRock Inc. purchased a new position in Zenas BioPharma in the second quarter worth $68,176,000. Bank of America Corp DE bought a new position in Zenas BioPharma in the 2nd quarter valued at $31,247,000. Polar Capital Holdings Plc bought a new position in Zenas BioPharma in the 4th quarter valued at $38,402,000. EcoR1 Capital LLC bought a new position in Zenas BioPharma in the 4th quarter valued at $28,667,000. Finally, Wellington Management Group LLP increased its holdings in Zenas BioPharma by 27.9% during the second quarter. Wellington Management Group LLP now owns 1,593,819 shares of the company’s stock worth $40,451,000 after buying an additional 347,766 shares during the last quarter.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for patients with serious autoimmune diseases. The company’s research is centered on medicines designed to modulate the immune system while potentially avoiding the broad immune-cell depletion associated with some existing treatments.

Zenas’ lead product candidate is obexelimab, an investigational monoclonal antibody designed to bind CD19 and FcγRIIb receptors on B cells. Through this mechanism, obexelimab is intended to inhibit B-cell activity without eliminating the cells.